Kiora Pharmaceuticals
Executivos
Veja o organograma con seus 10 executivos principais
Biografias mais buscadas da Kiora Pharmaceuticals
- Brian Strem, Director, President and Chief Executive Officer
- Praveen Tyle, Chairman of the Board
- Aron Shapiro, Director
Recentes movimentos de executivos em Kiora Pharmaceuticals
- Praveen Tyle antes Director, agora é Chairman of the Board (Notícia publicada em 27 de setembro de 2023).
- Paul Chaney, Chairman of the Board, se aposentou (Notícia publicada em 27 de setembro de 2023).
Criar um alerta
para seguir os movimentos de executivos da Kiora Pharmaceuticals.
Farmacêutica
Kiora Pharmaceuticals possui 1.861 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Kiora Pharmaceuticals
- The Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
- Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
- Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
- Association for Research in Vision and Ophthalmology (ARVO)
- Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
- Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
- Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
- Kiora Investor Webcast
- Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
- Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini
- View more press releases Close
Redes sociais sobre Kiora Pharmaceuticals
- Kiora Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Kiora Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Brian Strem 
Ligue para a Kiora Pharmaceuticals em +1 781...
